^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CTLA4 inhibitor

    Related drugs:
    3d
    A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=290, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin • Qibeian (iparomlimab/tuvonralimab)
    3d
    Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab. (PubMed, Immunooncol Technol)
    In the randomized SCANDIUM II trial, patients with metastatic UM received a one-time treatment with isolated hepatic perfusion using high-dose melphalan in combination with systemic immune checkpoint inhibition with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). Patients with undetectable ctDNA 2-4 months after the start of treatment had significantly improved progression-free survival (P = 0.024), and a non-significant improvement in overall survival. In patients with UM liver metastases treated with combined hepatic perfusion and immune checkpoint inhibition, ctDNA may serve as a predictive biomarker and warrants further validation.
    Journal • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • melphalan
    4d
    PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC. (PubMed, J Immunother Cancer)
    Patients with NSCLC and low TPS/high IC scores may benefit more from Nivo+Ipi than from Pembro due to distinct genomic and immunological features, including high TMB and Treg fraction.
    Observational data • Retrospective data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • TMB-H
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=21, Recruiting, Mary Feng, MD | Trial completion date: Feb 2027 --> Jul 2029 | Trial primary completion date: Feb 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    T Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma. (PubMed, Clin Cancer Res)
    These findings suggest that STRIDE and D+B have distinct, and potentially complementary, mechanisms of action in uHCC.
    PK/PD data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    CATALIS: Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial • Mismatch repair • MSI-H • dMMR
    |
    capecitabine • oxaliplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    7d
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Fudan University
    New trial • IO biomarker
    |
    Qibeian (iparomlimab/tuvonralimab)
    7d
    Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    7d
    CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy. (PubMed, Front Oncol)
    This study evaluated the therapeutic efficacy of Nivolumab/Ipilimumab plus Cytokine-Induced Killer (CIK) cells in ovarian carcinoma models. Concurrently, it induced substantial apoptosis in A2780 cells (3.2-fold increase, 22.8% vs 7.1% control), triggered pronounced G0/G1 phase arrest in SKOV3 (55% vs 40% control) with concomitant S-phase depletion, and inhibited wound closure capacity by 64.7% in combinatorial treatment groups. The triple-combination therapy synergistically enhances antitumor efficacy through potent G1/S checkpoint blockade, selective cytotoxicity against ICI-resistant populations, and migration-inhibitory activity, thus establishing CIK-ICI coadministration as a clinically translatable strategy for advanced ovarian malignancies.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    8d
    Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Akeso
    New P2 trial
    |
    cisplatin • paclitaxel • Kaitanni (cadonilimab)
    8d
    CA209-63Y: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (clinicaltrials.gov)
    P1/2, N=46, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Apr 2026 --> Sep 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Trodelvy (sacituzumab govitecan-hziy)